NDAORALSYRUP
Approved
Mar 1943
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
HYCODAN (hydrocodone bitartrate and homatropine methylbromide) by Teva is mu-opioid receptor, although it can interact with other opioid receptors at higher doses. First approved in 1943.
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYCODAN is an oral syrup combination of hydrocodone bitartrate (mu-opioid receptor agonist) and homatropine methylbromide (anticholinergic) approved in 1943 for cough suppression. Hydrocodone acts centrally on the cough center while homatropine provides anticholinergic effects, with the combination delivering efficacy in suppressing cough reflex. This is a legacy small-molecule antitussive indicated for symptomatic cough management in patients requiring opioid-based cough relief.
$0.235MPart D
LOE ApproachingMinimal commercial activity with only 13 Part D claims in 2023 suggests declining market relevance and likely small cross-functional team supporting legacy product maintenance.
Mechanism of Action
mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act centrally on the cough center. In excessive doses, hydrocodone will depress respiration.…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HYCODAN offers limited career growth potential given its LOE approaching status, minimal Part D claims (13 in 2023), and zero linked job openings in current market. Working on this legacy product would primarily involve portfolio maintenance and transition planning rather than growth or innovation opportunities.
Brand Manager
Worked on HYCODAN at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.